Company
Official Name: AbbVie Inc.
Headquarters: North Chicago, IL, United States
Founded: 2013
Employees: 50,000
CEO: Mr. Richard A. Gonzalez
$405.28 Billion
USD as of Jan. 1, 2026
AbbVie Inc. is a pharmaceutical company. It is dedicated to the research and development, manufacturing, and marketing of medicine for a number of chronic diseases including autoimmune diseases, leukemia, lymphoma, hepatitis C, and HIV. It is also engaged in the treatment of pancreatic, thyroidal, and other hormonal insufficiencies.
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| Roche | $332.12 B |
| AstraZeneca | $284.38 B |
| Novartis | $267.63 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
| AstraZeneca | $284.38 B |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $59.64 B |
| EBITDA | $18.19 B |
| Gross Profit TTM | $42.62 B |
| Profit Margin | 4.00% |
| Operating Margin | 35.50% |
| Quarterly Revenue Growth | 9.10% |
AbbVie Inc. has the following listings and related stock indices.
Stock: NYSE: ABBV
Stock: MTA: 4AB
Stock: BCBA: ABBV
Stock: BMV: ABBV
Stock: Bovespa: ABBV34
Stock: FSX: 4AB
Pharmaceutical drugsHumira (adalimumab)Imbruvica (ibrutinib)Venclexta (venetoclax)Zinbryta (daclizumab)Kaletra (lopinavir)Norvir (ritonavir)Mavyret/Maviret (glecaprevir/pibrentasvir)Skyrizi (risankizumab)
Richard A. Gonzalez (Chairman and CEO) Michael Severino (Vice Chairman and President)